FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 21, Issue 7, Pages 2096-2101
Publisher
Baishideng Publishing Group Inc.
Online
2017-09-18
DOI
10.3748/wjg.v21.i7.2096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
- (2014) R. Buzzoni et al. ANNALS OF ONCOLOGY
- S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
- (2014) A B El-Khoueiry et al. BRITISH JOURNAL OF CANCER
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
- (2014) L Fornaro et al. BRITISH JOURNAL OF CANCER
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- Second-line therapy in advanced biliary tract cancer: What should be the standard?
- (2013) Stefano Cereda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Accelerator Leak Halts Japanese Physics Experiments
- (2013) D. Normile SCIENCE
- Chemotherapy for cholangiocarcinoma: An update
- (2013) Natalia Ramírez-Merino World Journal of Gastrointestinal Oncology
- Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2
- (2012) Olivier Mir et al. ANTI-CANCER DRUGS
- Chemotherapy for Inoperable Advanced or Metastatic Cholangiocarcinoma: Retrospective Analysis of 78 Cases in a Single Center over Four Years
- (2012) Marc Pracht et al. CHEMOTHERAPY
- Outcome of second-line chemotherapy for biliary tract cancer
- (2012) John Bridgewater et al. EUROPEAN JOURNAL OF CANCER
- HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
- (2012) Joshua Peck et al. ONCOLOGY
- A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
- (2011) Jun Ho Yi et al. EUROPEAN JOURNAL OF CANCER
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Dramatic Response to Panitumumab and Bevacizumab in Metastatic Gallbladder Carcinoma
- (2011) E. Riley et al. ONCOLOGIST
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started